- Conditions
- Childhood CNS Tumor
- Interventions
- SGT-53, Radiation, Irinotecan, Temozolomide, Bevacizumab
- Genetic · Radiation · Drug
- Lead sponsor
- SynerGene Therapeutics, Inc.
- Industry
- Eligibility
- 1 Year to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 71
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Glioma, Glioblastoma, Glioblastoma Multiforme, GBM, Brain Cancer
- Interventions
- VAL-083 (Dianhydrogalactitol)
- Drug
- Lead sponsor
- Kintara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 5
- States / cities
- San Francisco, California • Denver, Colorado • Sarasota, Florida + 2 more
- Conditions
- Glioblastoma
- Interventions
- Bevacizumab, Temozolomide, Radiation therapy, Placebo
- Drug · Radiation
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 921 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more
- Conditions
- Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Interventions
- vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, temozolomide, temsirolimus, bevacizumab, sorafenib, surgery, radiation
- Drug · Procedure · Radiation
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Glioma
- Interventions
- Temozolomide and Bevacizumab
- Drug
- Lead sponsor
- Kentuckiana Cancer Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Refractory Solid Tumors in Children
- Interventions
- Irinotecan, Vincristine, Temozolomide, Bevacizumab
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 12 Months to 20 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Glioblastoma Multiforme, Gliosarcoma
- Interventions
- Avastin, Temozolomide, Irinotecan
- Drug
- Lead sponsor
- Katy Peters
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Glioblastoma Multiforme
- Interventions
- Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine
- Drug · Radiation · Device
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
- Conditions
- Central Nervous System Tumors
- Interventions
- Bevacizumab, Irinotecan, Temozolomide
- Drug
- Lead sponsor
- Johns Hopkins All Children's Hospital
- Other
- Eligibility
- 18 Months to 23 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Neuroendocrine Tumors
- Interventions
- Bevacizumab, Temozolomide
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Interventions
- Temozolomide, hypofractionated radiation therapy, bevacizumab, questionnaire administration
- Drug · Radiation · Biological + 1 more
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Lake Forest, Illinois • Naperville, Illinois + 1 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- Bevacizumab
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Metastatic Melanoma, Brain Metastases
- Interventions
- nab-paclitaxel, Temozolomide, Bevacizumab
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Tucson, Arizona
- Conditions
- Glioblastoma Multiforme
- Interventions
- Bevacizumab and Temozolomide
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Evanston, Illinois • Ann Arbor, Michigan + 2 more
- Conditions
- High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
- Interventions
- nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab, nab-sirolimus + lomustine, nab-sirolimus + marizomib (MRZ), nab-sirolimus + temozolomide + radiotherapy
- Drug
- Lead sponsor
- Aadi Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Fullerton, California • Newport Beach, California • Santa Monica, California
- Conditions
- Recurrent Glioblastoma Multiforme, Recurrent Gliosarcoma
- Interventions
- temozolomide and bevacizumab
- Drug
- Lead sponsor
- Center for Neurosciences, Tucson
- Other
- Eligibility
- 18 Years to 83 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Recurrent Pancreatic Cancer, Somatostatinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Interventions
- Capecitabine, Temozolomide, Bevacizumab
- Drug · Biological
- Lead sponsor
- Shaheen Shagufta
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Cancer
- Interventions
- Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, Nivolumab + Relatlimab, Capecitabine, Bevacizumab, Temozolomide, Rucaparib, Daratumumab, Regorafinib, Leucovorin, Fluorouracil, Oxaliplatin, Enzalutamide, Sunitinib, Pemetrexed, Pembrolizumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 59
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Lynwood, California + 46 more
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Temo + Avastin, VP-16 + Avastin
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Glioblastoma Multiforme
- Interventions
- Radiation therapy, Temozolomide, Bevacizumab, Everolimus
- Radiation · Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 13
- States / cities
- Huntsville, Alabama • Fort Myers, Florida • Gainesville, Georgia + 10 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- bevacizumab, erlotinib hydrochloride
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Orlando, Florida • Chicago, Illinois + 5 more
- Conditions
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
- Interventions
- NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab
- Drug
- Lead sponsor
- Neonc Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- bevacizumab, temozolomide, external beam radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Glioblastoma Multiforme, Gliosarcoma
- Interventions
- Gliadel, Radiation Therapy, Avastin, Temodar
- Drug · Radiation
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina